NL-OMON47145已完成2 期
A multicenter, randomized, placebo-controlled, parallel group, double blind, dose-finding Phase II trial to study the efficacy, safety, pharmacokinetic and pharmacodynamic effects of the oral partial adenosine A1 receptor agonist neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fraction - PANTHEO
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Bayer
- 入组人数
- 30
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 99（—）
入选标准
- •1. Men or women aged 18 years and older
- •2. Diagnosis of chronic heart failure (CHF), NYHA class II-IV, LVEF * 35% and Elevated NT-proBNP
排除标准
- •1. Acute de-novo heart failure
- •2. Requirement of any intravenous (IV) treatments following 48 hours prior to randomization:
- •3 Mechanical support (e.g. intra-aortic balloon pump, endotracheal intubation, mechanical ventilation, or any ventricular assist device)
- •4. Any cause of chronic heart failure other than ischemic cardiomyopathy and idiopathic dilated cardiomyopathy
研究者
相似试验
进行中（未招募）
不适用
Double-blind, placebo-controlled, parallel group, study of ICS/LABA/LAMA on cough symptoms in adult patients with asthmaBronchial asthmaJPRN-jRCTs031210412Tagaya Etsuko60
进行中（未招募）
1 期
A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fractiochronic heart failure with reduced ejection fraction (LVEF equal or below 35%)MedDRA version: 20.0Level: LLTClassification code 10066498Term: Cardiac failure chronic aggravatedSystem Organ Class: 100000004849EUCTR2016-003839-38-ITBAYER AG427
进行中（未招募）
1 期
A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fractiochronic heart failure with reduced ejection fraction (LVEF equal or below 35%)EUCTR2016-003839-38-DEBayer AG427
进行中（未招募）
1 期
PANACHE - A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with preserved ejection fractioEUCTR2016-004062-26-BEBayer AG305
进行中（未招募）
1 期
A phase II trial to study neladenoson bialanate over 20 weeks in patients with chronic heart failure with reduced ejection fractiochronic heart failure with reduced ejection fraction (LVEF equal or below 35%)EUCTR2016-003839-38-GRBayer AG384